Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN17235 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 Dose Escalation | EXPERIMENTAL | - |
| Part 2 Safety Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN17235 | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Presence of SF3B1 mutation in the bone marrow or peripheral blood AND diagnosis of low-risk MDS OR diagnosis of CCUS as defined by WHO 2022, 5th edition as described in the protocol 2. Adequate bone marrow function as described in the protocol; red blood cell transfusion ...
REGN17235 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of Clonal Cytopenia of Undetermined Significance (CCUS) and low-risk myelodysplastic syndrome with SF3B1 mutation. It is currently in Phase 1 clinical development.
REGN17235 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The drug is currently in Phase 1 clinical trials.
REGN17235 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial is currently planned to evaluate its safety and tolerability in adult participants.
REGN17235 is being studied in a Phase 1 clinical trial with the identifier NCT07753148. The trial is designed to evaluate the safety and tolerability of REGN17235 in adult participants with Clonal Cytopenia of Undetermined Significance and low-risk myelodysplastic syndrome with SF3B1 mutation. The trial has not yet started recruiting.
REGN17235 is the sole name provided for this investigational drug. It is not known to be marketed under any other name. The drug is being developed by Regeneron Pharmaceuticals for hematologic conditions.